A PHARMACEUTICAL COMPOSITON CONTAINING SKULLCAPFLAVONE II OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF FOR THE PREVENTION OR TREATMENT OF ASTHMA

摘要

The present invention relates to a pharmaceutical composition containing skullcapflavone II or a pharmaceutically acceptable salt thereof as an active ingredient for preventing or treating asthma. Specifically, skullcapflavone II compounds suppress body weight reduction caused by asthma, the generation of IgE, ovoalbumin-specific IgE, interleukin-4, 5, and 13, and MMP-9 in serum and a bronchoalveolar lavage fluid, alleviate airway hypersensitivity responses, and prevent collagen precipitation around bronchial tubes, inflammatory cell infiltration into bronchial tubes, and mucous secretion in bronchial tubes with low hepatotoxicity. In addition, the skullcapflavone II compounds reduce the concentration of TGF-beta 1, increase the expression of Smad7, and suppress the concentration of pSmad2/3, thereby being used as an active ingredient of a pharmaceutical composition for preventing or treating bronchial asthma. [Reference numerals] (AA) Gold E3-PR-13 (skullcapflavone ii);(BB) Document: Chem. Pharm. Bull. (1980), 28(3), 708-716;(CC) C (document) (DMSO-d_s)